bioRxiv Science⌕ Search

Biology subjects

Duttargi, A.

Publications and source records attributed to Duttargi, A..

2 recordsLinked to original sources

Natural killer cells associate with epithelial cells in the pancreatic ductal adenocarcinoma tumor microenvironment

Pancreatic ductal adenocarcinoma (PDAC) exhibits dense fibrosis and immune exclusion. While fibrosis has been studied globally and at the region-of-interest level, its impact on stromal-ductal architecture and immune cell localization remains unknown. Here, we establish cancer-associated fibroblast (CAF)-stratified ductal spatial architecture as a fundamental determinant of immune exclusion in PDAC. Focusing on malignant PDAC epithelial ductal regions, the critical interface where immune cells must access tumor epithelium, we demonstrate that periductal fibroblast organization dictates leukocyte proximity. Through integrative analysis of treatment-naive patient samples from three independent cohorts - including imaging mass cytometry, multiplex immunohistochemistry, and single-cell RNA sequencing - we uncovered that activated, pro-inflammatory leukocytes preferentially localized near malignant ducts in regions with low fibroblast density. Stratifying epithelial-ductal regions by CAF abundance revealed a graded constraint: increasing fibroblast content corresponded to reduced leukocyte-epithelial proximity and elevated collagen I deposition. Despite their exclusion in high-CAF ducts, leukocytes in low-CAF ducts retained functional competence. Mechanistically, ligand-receptor inference implicated collagen-CD44 signaling as an adhesion axis anchoring immune cells within fibroblast-rich zones, with CD44 blockade enhancing natural killer cell invasion and motility in fibrotic spheroid models. Thus, by establishing ductal regions as critical spatial units of immune exclusion, these findings provide a framework for dissecting stromal-immune interactions and reveal targetable "stromal checkpoints" that can be leveraged to overcome CAF-driven barriers to leukocyte motility and infiltration in PDAC. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=111 SRC="FIGDIR/small/593868v3_ufig1.gif" ALT="Figure 1"> View larger version (30K): org.highwire.dtl.DTLVardef@17df874org.highwire.dtl.DTLVardef@142c809org.highwire.dtl.DTLVardef@15af4a7org.highwire.dtl.DTLVardef@74183a_HPS_FORMAT_FIGEXP M_FIG C_FIG

cancer biology↗

The orphan nuclear receptor estrogen-related receptor beta (ERRβ) in triple-negative breast cancer

PurposeTriple negative breast cancer (TNBC)/ basal-like breast cancer (BLBC) is a highly aggressive form of breast cancer prevalent in African-American (AA) women. We previously reported that a small molecule agonist ligand for the orphan nuclear receptor estrogen-related receptor beta (ERR{beta} or ESRRB) has growth inhibitory and anti-mitotic activity in TNBC cell lines. In this study, we evaluate the association of ESRRB mRNA, copy number levels, and protein expression with demographic, clinicopathological, and gene expression features in breast tumor clinical specimens.\n\nMethodsESRRB mRNA level expression and clinical associations were analyzed using RNAseq data. Array-based comparative genomic hybridization determined ESRRB copy number in AA and Caucasian women. Transcription factor activity was measured using promoter-reporter luciferase assays in TNBC cell lines. Semi-automatic quantification of immunohistochemistry measured ERR{beta} protein expression on a 150-patient tissue microarray series.\n\nResultsESRRB mRNA expression is significantly lower in TNBC/BLBC vs. other breast cancer subtypes. There is no evidence of ESRRB copy number loss. ESRRB mRNA expression is correlated with the expression of genes associated with neuroactive ligand-receptor interaction, metabolic pathways, and deafness. These genes contain G/C-rich transcription factor binding motifs. The ESRRB message is alternatively spliced into three isoforms, which we show have different transcription factor activity in basal-like vs. other TNBC cell lines. We further show that the ERR{beta}2 and ERR{beta}sf isoforms are broadly expressed in breast tumors at the protein level.\n\nConclusionsDecreased ESRRB mRNA expression, and distinct patterns of ERR{beta} isoform subcellular localization and transcription factor activity are key features in TNBC/BLBC.

cancer biology↗